Bedaquiline for multidrug-resistant TB in paediatric patients
THINK’s first paediatric study, sponsored by Janssen Pharmaceuticals, started in May 2015 headed by Dr Ronelle Moodliar at the King Dinuzulu clinical trial site. The study was supported by Seshni Moorgas as the trial coordinator together with Nokuthula Ngcobo and Lungile Phakatias the research nurses. The study contributed towards more than 50% of the total recruited patients globally for cohorts 1 and 2 (>5 to <18 years) and is currently enrolling children into the >2 to <5-year cohort. Through the successful achievements of this study thus far, the paediatric dosage and formulation for the age groups of 5-18-years have now [...]